Tao, Ye Chen, Zhongping
Background: Effective drug delivery of nanomedicines to targeted sites remains challenging. Given that hypobaric hypoxia and hyperbaric oxygen exposure can significantly change pharmacokinetics of drugs, it is interesting to determine whether they can regulate tissue distribution of nanomedicine, especially in tumor, for enhanced cancer therapy. Re...
Luna, Sofia E Camarena, Joab Hampton, Jessica P Majeti, Kiran R Charlesworth, Carsten T Soupene, Eric Selvaraj, Sridhar Jia, Kun Sheehan, Vivien A Cromer, M Kyle
...
Some gene polymorphisms can lead to monogenic diseases, whereas other polymorphisms may confer beneficial traits. A well-characterized example is congenital erythrocytosis-the non-pathogenic hyper-production of red blood cells-that is caused by a truncated erythropoietin receptor. Here we show that Cas9-mediated genome editing in CD34+ human haemat...
Roeker, Lindsey E Coombs, Catherine C Shah, Nirav N Jurczak, Wojciech Woyach, Jennifer A Cheah, Chan Y Patel, Krish Maddocks, Kami Wang, Yucai Zinzani, Pier Luigi
...
IntroductionPirtobrutinib, a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor, has demonstrated promising efficacy in B-cell malignancies and is associated with low rates of discontinuation and dose reduction. Pirtobrutinib is administered until disease progression or toxicity, necessitating an understanding of the safety...
Casselini, Carolina M Parson, Henri K Frizzi, Katie E Marquez, Alex Smith, Darrell R Guernsey, Lucie Nemmani, Rakesh Tayarani, Alireza Jolivalt, Corinne G Weaver, Jessica
...
Preclinical studies indicate that diverse muscarinic receptor antagonists, acting via the M1 sub-type, promote neuritogenesis from sensory neurons in vitro and prevent and/or reverse both structural and functional indices of neuropathy in rodent models of diabetes. We sought to translate this as a potential therapeutic approach against structural a...
Alidoost, Mohammadali Wilson, Jennifer L
Modeling tools aim to predict potential drug side effects, although they suffer from imperfect performance. Specifically, protein-protein interaction models predict drug effects from proteins surrounding drug targets, but they tend to overpredict drug phenotypes and require well-defined pathway phenotypes. In this study, we used PathFX, a protein-p...
Selvaraj, Sridhar Feist, William N Viel, Sebastien Vaidyanathan, Sriram Dudek, Amanda M Gastou, Marc Rockwood, Sarah J Ekman, Freja K Oseghale, Aluya R Xu, Liwen
...
Therapeutic applications of nuclease-based genome editing would benefit from improved methods for transgene integration via homology-directed repair (HDR). To improve HDR efficiency, we screened six small-molecule inhibitors of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a key protein in the alternative repair pathway of non-homologo...
Mudde, Anne CA Kuo, Caroline Y Kohn, Donald B Booth, Claire
During the past 20 years, gene editing has emerged as a novel form of gene therapy. Since the publication of the first potentially therapeutic gene editing platform for genetic disorders, increasingly sophisticated editing technologies have been developed. As with viral vector-mediated gene addition, inborn errors of immunity are excellent candidat...
Lance‐Byrne, Alissa Lindquist‐Kleissler, Brent Johnstone, Timothy C
Abstract: Structure elucidation plays a critical role across the landscape of medicinal chemistry, including medicinal inorganic chemistry. Herein, we discuss the importance of structure elucidation in drug development and then provide three vignettes that capture key instances of its relevance in the development of biologically active inorganic co...
Liang, Christopher Paclibar, Cayz G Gonzaga, Noresa L Sison, Stephanie A Bath, Harman S Biju, Agnes P Mukherjee, Jogeshwar
Therapeutic antibodies for reducing Aβ plaque load in Alzheimer’s disease (AD) is currently making rapid progress. The diagnostic imaging of Aβ plaque load in AD has been underway and is now used in clinical studies. Here, we report our preliminary findings on imaging a therapeutic antibody, Lecanemab, in a postmortem AD brain anterior cingulate. [...
Samadi, Amirmasoud Moammeri, Ali Azimi, Shamim Bustillo-Perez, Bexi M Mohammadi, M Rezaa
The current paradigm of medicine is mostly designed to block or prevent pathological events. Once the disease-led tissue damage occurs, the limited endogenous regeneration may lead to depletion or loss of function for cells in the tissues. Cell therapy is rapidly evolving and influencing the field of medicine, where in some instances attempts to ad...